GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. lowered its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 7.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 220,609 shares of the company's stock after selling 17,465 shares during the quarter. Braun Stacey Associates Inc.'s holdings in GE HealthCare Technologies were worth $20,704,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of GEHC. Quent Capital LLC boosted its stake in GE HealthCare Technologies by 18.4% during the 3rd quarter. Quent Capital LLC now owns 766 shares of the company's stock worth $72,000 after purchasing an additional 119 shares during the period. Greenleaf Trust raised its holdings in shares of GE HealthCare Technologies by 1.7% in the third quarter. Greenleaf Trust now owns 7,619 shares of the company's stock valued at $715,000 after buying an additional 124 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of GE HealthCare Technologies by 8.7% during the second quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company's stock worth $135,000 after buying an additional 127 shares during the period. Quarry LP grew its holdings in shares of GE HealthCare Technologies by 28.3% during the second quarter. Quarry LP now owns 594 shares of the company's stock worth $46,000 after buying an additional 131 shares during the last quarter. Finally, Harbour Investments Inc. increased its position in GE HealthCare Technologies by 4.3% in the 3rd quarter. Harbour Investments Inc. now owns 3,164 shares of the company's stock valued at $297,000 after acquiring an additional 131 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Price Performance

NASDAQ:GEHC traded up $0.99 during mid-day trading on Monday, hitting $82.75. 1,636,159 shares of the company's stock traded hands, compared to its average volume of 3,041,777. GE HealthCare Technologies Inc. has a 1 year low of $66.39 and a 1 year high of $94.55. The company has a market cap of $37.81 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.93 and a beta of 1.24. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The firm's 50 day simple moving average is $88.70 and its 200 day simple moving average is $83.51.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.08. The business had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.99 earnings per share. Sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.29 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Friday, October 18th were paid a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a yield of 0.15%. The ex-dividend date of this dividend was Friday, October 18th. GE HealthCare Technologies's payout ratio is 3.30%.

Analyst Upgrades and Downgrades

GEHC has been the subject of a number of recent research reports. Wells Fargo & Company increased their price objective on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a research report on Thursday, October 31st. BTIG Research upgraded shares of GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a research note on Wednesday, September 18th. Redburn Atlantic upgraded shares of GE HealthCare Technologies to a "strong-buy" rating in a research report on Thursday, August 1st. UBS Group cut GE HealthCare Technologies from a "neutral" rating to a "sell" rating and dropped their target price for the stock from $84.00 to $74.00 in a research report on Thursday, September 26th. Finally, JPMorgan Chase & Co. started coverage on GE HealthCare Technologies in a report on Monday, September 9th. They set a "neutral" rating and a $90.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, GE HealthCare Technologies has an average rating of "Moderate Buy" and a consensus price target of $94.36.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total value of $309,338.96. Following the transaction, the chief executive officer now owns 24,298 shares in the company, valued at $2,101,291.04. This trade represents a 12.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.27% of the stock is owned by company insiders.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.